You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Our Medicines

Dovato packshot

DOVATO (dolutegravir/lamivudine)

View Details

DOVATO is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 1

Dovato Summary of Product Characteristics

Download Dovato Post Prescription Booklet

Learn More | Juluca

JULUCA▼(dolutegravir/rilpivirine)

View Details

JULUCA is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI. 2

Juluca Summary of Product Characteristics

Download Juluca Post Prescription Booklet

Order: Juluca Patient Information Guide

TRIUMEQ (dolutegravir/abacavir/lamivudine)

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. 3

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patient known to carry the HLA-B*5701
allele.
3

Triumeq Summary of Product Characteristics

Download: Triumeq Post Prescription Booklet

Order: Triumeq Patient Information Guide

Information on abacavir hypersensitivity reaction

Learn More | Tivicay

TIVICAY (dolutegravir)

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age. 4

Tivicay Summary of Product Characteristics

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.